Kestra Medical Technologies Inc
NASDAQ:KMTS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kestra Medical Technologies Inc
NASDAQ:KMTS
|
US |
|
PolyPid Ltd
NASDAQ:PYPD
|
IL |
|
R
|
Romi SA
BOVESPA:ROMI3
|
BR |
|
PR Times Inc
TSE:3922
|
JP |
|
C
|
C&G Hi Tech Co Ltd
KOSDAQ:264660
|
KR |
|
I
|
Iveric Bio Inc
F:O2T
|
US |
|
BW LPG Ltd
OSE:BWLPG
|
SG |
|
Biotage AB
STO:BIOT
|
SE |
|
Perimeter Medical Imaging AI Inc
XTSX:PINK
|
CA |
Kestra Medical Technologies Inc
Kestra Medical Technologies Ltd. operates as a commercial-stage, wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington. The company went IPO on 2025-03-06. The firm is focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies. The company has developed and commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform include the ASSURE WCD, a next generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm. In addition to the ASSURE WCD, its Cardiac Recovery System platform includes a comprehensive suite of fully integrated digital solutions and services.
Kestra Medical Technologies Ltd. operates as a commercial-stage, wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington. The company went IPO on 2025-03-06. The firm is focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies. The company has developed and commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform include the ASSURE WCD, a next generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm. In addition to the ASSURE WCD, its Cardiac Recovery System platform includes a comprehensive suite of fully integrated digital solutions and services.
Revenue: Revenue was $24.6 million in the third quarter, up 63% year‑over‑year, driven by prescription growth and higher revenue per fit.
Prescriptions: Kestra accepted over 5,400 ASSURE prescriptions in the quarter and management said the business is approaching about 20,000 prescriptions for fiscal 2026.
Margins: Gross margin expanded to 52.6% (up 9 points YoY and +200 bps sequentially); management reiterated a path to 70%+ gross margins over the next few years.
Market & evidence: Management cited ACE‑PAS (21,000+ patients) and other clinical data as drivers of broader WCD adoption and announced an FDA algorithm update expected to lower false alarms and inappropriate shocks.
Commercial & access: Field expansion continues (about 100 active territories at end of 2025, targeting ~130 by April), plus new reimbursement wins: Florida managed Medicaid approvals, Department of Veterans Affairs federal supply schedule listing, and Medicare monthly rate increased to $3,589.
Profitability & cash: GAAP net loss was $34.2 million; adjusted EBITDA loss was $21.2 million. Cash totaled $291 million as of January 31; company raised capital in December and plans a shelf filing in April.
Guidance: Fiscal 2026 revenue guidance was raised to $93.0 million (growth of 55%), up from prior guidance of $91.0 million.
